FDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood Disorder
November 08 2019 - 1:20PM
Dow Jones News
By Stephen Nakrosis
The U.S. Food and Drug Administration on Friday said it granted
approval to Reblozyl to treat some anemia patients.
Celgene Corp. (CELG) and Acceleron Pharma Inc. (XLRN) are
jointly developing Reblozyl as part of a global collaboration, the
companies said.
The FDA said it was the first therapy to treat patients anemia
patients with beta thalassemia who require regular red blood cell
transfusions.
Beta thalassemia, or "Cooley's anemia," is a blood disorder that
reduces the production of hemoglobin in red blood cells, the FDA
said.
"Today's approval is an important milestone and underscores our
continued commitment to patients with hematology disorders," said
Nadim Ahmed, President, Global Hematology and Oncology for Celgene.
"There are very limited options for patients living with anemia due
to beta thalassemia who are dependent on long term red blood cell
transfusions."
Habib Dable, president and chief executive of Acceleron, said,
"We're thrilled that Acceleron's first approved medicine is one
with the potential to help patients with beta thalassemia, who have
been in need of new treatments for this lifelong disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2019 13:05 ET (18:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Dec 2023 to Dec 2024
